Cells can donate their mitochondria to damaged neighbors, and researchers are learning how to harness that process to treat stroke, heart attacks, diabetic wounds, and more. The basic phenomenon has been known for roughly two decades, but recent years have brought a surge of mechanistic detail, engineered delivery systems, and the first human clinical trials. What was once a biological curiosity is now a rapidly developing therapeutic strategy with implications across nearly every organ system.
How Cells Move Mitochondria to One Another
Cells do not simply dump mitochondria into the surrounding fluid and hope for the best. They have at least two well-characterized delivery routes. The first involves tunneling nanotubes, thin tubes made of actin that physically bridge one cell to another. These structures allow organelles to travel directly between connected cells, sometimes over surprisingly long distances. A protein called Miro1 appears to be a central player, linking mitochondria to the cell’s internal transport machinery and enabling them to slide along the nanotube like cargo on a rail.1PubMed Central. Mechanisms of Mitochondrial Transfer Through TNTs: From Organelle Dynamics to Cellular Crosstalk Work on sepsis-related heart damage has shown that another protein, Drp1, drives the actual construction of these nanotubes by remodeling the cell’s structural scaffolding, interacting with filamin and kinesin to build and extend the tubes for long-range trafficking.2PubMed Central. Cytoskeletal remodeling promotes tunneling nanotube formation and drives cardiac resident cell mitochondrial transfer in sepsis
The second route uses extracellular vesicles, small membrane-wrapped packets that cells release into their surroundings. These vesicles can carry mitochondrial DNA, mitochondrial proteins, and in some cases whole intact mitochondria.3PubMed. Extracellular vesicles meet mitochondria: Potential roles in regenerative medicine Researchers studying neural stem cells found that the mitochondria inside these vesicles retained their membrane potential and could still carry out respiration, meaning they arrived at their destination alive and working. When those vesicles were given to cells completely lacking functional mitochondria, they restored mitochondrial activity and improved cell survival.4PLOS Biology. Neural stem cells traffic functional mitochondria via extracellular vesicles
Both routes seem to operate under stress conditions especially well. Damaged cells appear to send distress signals that attract mitochondrial donations from nearby healthy cells, while healthy stem cells can actively push their mitochondria outward toward struggling neighbors.5PubMed Central. Mitochondria Donation by Mesenchymal Stem Cells: Current Understanding and Mitochondria Transplantation Strategies This two-way communication, where injured cells call for help and donor cells respond, forms the biological foundation that therapeutic approaches are now trying to replicate and amplify.
What Happens After Mitochondria Arrive
A donated mitochondrion does not just sit passively in its new cell. Live-cell imaging has shown that transferred mitochondria begin fusing with the recipient cell’s own mitochondrial network within about 20 to 30 minutes of arrival, and this integration process continues for more than 16 hours.6PubMed Central. Mitochondria transplantation between living cells The donor’s mitochondrial DNA can even incorporate into the recipient’s mitochondrial genome.7PubMed Central. Mitochondria transplantation/transfer between single cells Not every transplanted mitochondrion succeeds, though. Some are accepted and fused into the network, while others are tagged for degradation and broken down by the cell’s quality-control machinery. The recipient cell essentially sorts through the incoming cargo, keeping what helps and discarding the rest.
This rapid integration is what makes therapeutic transplantation plausible. If transferred mitochondria were simply degraded on arrival, the whole concept would collapse. Instead, the evidence points to genuine metabolic rescue: cells that receive healthy mitochondria ramp up their energy production, suppress self-destruction pathways, and resume more normal function. The speed of fusion also matters clinically, because in conditions like stroke or heart attack, every minute of energy failure causes more tissue death.
Protecting the Brain After Stroke
Some of the most compelling evidence for mitochondrial transfer as a natural repair mechanism comes from stroke research. In a landmark mouse study, astrocytes (the support cells of the brain) were shown to release functional mitochondria after a stroke, and nearby neurons took them up. This transfer amplified survival signaling in the neurons. When the researchers suppressed CD38, a protein involved in releasing mitochondria from astrocytes, fewer mitochondria made it to neurons and neurological outcomes got worse.8PubMed Central. Transfer of mitochondria from astrocytes to neurons after stroke That finding was striking because it suggested the brain already has a built-in mitochondrial rescue system, and that interfering with it makes damage worse.
More recent work has identified additional molecular details. A receptor called LRP1 on astrocytes promotes this astrocyte-to-neuron mitochondria transfer by altering how the astrocyte handles lactate, a metabolic byproduct. When LRP1 is lost from astrocytes, the transfer falters and stroke damage worsens.9Cell Metabolism. Astrocytic LRP1 protects against ischemic stroke by enabling mitochondria-mediated astrocyte-neuron crosstalk The neural stem cell work mentioned earlier also connects here: when stem cells carrying functional mitochondria in vesicles were transplanted into an animal model of multiple sclerosis, they transferred those mitochondria to immune cells in the brain and significantly reduced clinical symptoms.4PLOS Biology. Neural stem cells traffic functional mitochondria via extracellular vesicles The brain, it turns out, may be one of the organs most naturally primed for this kind of mitochondrial sharing.
Heart Repair and Engineered Delivery
Heart tissue is exquisitely sensitive to energy deprivation. During a heart attack, blood flow to part of the heart muscle is cut off, and the mitochondria in those starved cells quickly fail. Even when blood flow is restored, the sudden rush of oxygen triggers oxidative stress that causes further mitochondrial damage. This creates a vicious cycle: cells that most need energy are the ones least able to produce it. Mitochondrial transfer targets exactly this problem.
In damaged heart tissue, cells have been shown to release dysfunctional mitochondria as a kind of distress signal, while taking up functional mitochondria from donor cells to reduce injury.10PubMed Central. Mitochondrial Transfer in Cardiovascular Disease: From Mechanisms to Therapeutic Implications Laboratory experiments with cultured heart cells demonstrated that transplanting isolated mitochondria reduced cell death after oxidative stress. Using a specialized delivery peptide called TAT to shuttle the mitochondria into cardiomyocytes made the effect even stronger, cutting the rate of cell death compared to simply adding bare mitochondria.11PubMed Central. TAT-dextran-mediated mitochondrial transfer enhances recovery from models of reperfusion injury in cultured cardiomyocytes
Getting mitochondria to survive the trip from bench to beating heart is a major engineering challenge. Isolated mitochondria are fragile. They lose membrane potential and stop working within hours if left unprotected. Two recent approaches tackle this in different ways. One group developed gelated microvesicles, essentially tiny gel beads coated with a molecule that heart cells preferentially absorb, which improved how efficiently cardiomyocytes took up the cargo and improved their mitochondrial networks after oxidative damage.12PubMed Central. Gelated microvesicle-mediated delivery of mesenchymal stem cell mitochondria for the treatment of myocardial infarction Another team designed a thermosensitive hydrogel that uses phase separation to condense and protect freshly isolated mitochondria. The gel remains injectable at body temperature and releases its mitochondrial cargo rapidly after transplantation, while the gel’s structure preserves mitochondrial activity through spatial confinement and calcium chelation.13PubMed Central. Transplantation of active mitochondria condensed in liquid-liquid phase-separated hydrogels ameliorates myocardial ischemia-reperfusion injury Calcium is relevant because high calcium concentrations in the extracellular environment can trigger the permeability transition pore in mitochondria, essentially popping them open and destroying them before they reach their target cells.
The Immune System’s Surprising Tolerance
Any time you transplant biological material from one individual to another, immune rejection is a concern. Organ transplants require immunosuppressive drugs. Blood transfusions require matching. So it would be reasonable to expect that injecting foreign mitochondria would provoke an immune response. The evidence so far suggests it does not, at least not in the dramatic way that whole-cell transplants do.
In mouse experiments, neither single nor multiple injections of mitochondria from genetically different donors triggered a significant immune response in terms of inflammatory signaling molecules or antibody production. By contrast, injecting whole cells from a different strain reliably provoked strong immune reactions. The mitochondria-treated mice also showed longer skin graft survival times compared to mice that had been sensitized with donor cells, and the mitochondrial injections did not raise circulating levels of mitochondrial DNA or damage-associated molecular patterns, molecules that can trigger inflammation.14Circulation. Absence of Immune Response to Syngeneic or Allogeneic Mitochondria Transplantation
This finding is encouraging but needs context. Most of this immune data comes from animal studies, and the long-term safety of repeated mitochondrial transplants in humans, particularly from donors rather than from the patient’s own cells, remains an open question.15PubMed Central. Therapeutic potential of mitochondrial transplantation in modulating immune responses post-cardiac arrest: a narrative review Still, the early data are more reassuring than many researchers initially expected, and they suggest that mitochondria may occupy a kind of immunological blind spot, possibly because of their evolutionary origin as former bacteria that have been part of eukaryotic cells for over a billion years.
Boosting Immune Cells Against Cancer
Not all mitochondrial transfer is about repairing damaged tissue. One of the most exciting recent findings involves supercharging the immune system’s own cancer-fighting cells. Researchers found that bone marrow stromal cells form tunneling nanotubes with CD8+ T cells, the immune cells responsible for killing tumor cells, and pass mitochondria through those connections. The nanotubes connecting human cells were longer and wider than those in mice, with some human nanotubes exceeding 40 micrometers in length, and certain segments bulging out to accommodate the mitochondria passing through them.16Cell. Mitochondrial transfer empowers CD8+ T cell antitumor immunity The transfer boosted the T cells’ antitumor activity, a finding with obvious implications for immunotherapy.
But mitochondrial transfer can also work against you in cancer. Tumor cells exploit the same tunneling-nanotube machinery to acquire mitochondria from surrounding stromal and immune cells, fueling their metabolism, enabling immune evasion, and building resistance to chemotherapy and radiation.17PubMed Central. Mitochondrial transfer in cancer: mechanisms, immune evasion, and therapeutic opportunities In glioblastoma, the most aggressive type of brain cancer, mesenchymal stem cells were found to donate mitochondria to tumor stem cells through nanotubes, making those cancer cells more resistant to the standard chemotherapy drug temozolomide. The mechanism involved a metabolic shift: the cancer cells rewired their energy metabolism to rely on different fuel sources. Promisingly, blocking a key enzyme in this rewired pathway with a drug called brequinar restored the cancer cells’ sensitivity to chemotherapy.18Cancer Research Communications. Mitochondria Transfer from Mesenchymal Stem Cells Confers Chemoresistance to Glioblastoma Stem Cells through Metabolic Rewiring
This double-edged nature makes mitochondrial transfer in oncology both a therapeutic opportunity and a hazard. Any future mitochondrial therapy for patients with cancer or a history of it will need to account for the possibility that transplanted mitochondria could be hijacked by tumor cells.
Healing Diabetic Wounds
Chronic wounds in people with diabetes are notoriously difficult to heal. Part of the problem is that macrophages, the immune cells responsible for clearing debris and coordinating tissue repair, get stuck in an inflammatory state. They keep producing pro-inflammatory signals instead of switching to a reparative mode. Mitochondrial dysfunction in these macrophages is a central driver of this inflammatory lock.
Two recent animal studies have shown that delivering functional mitochondria to diabetic wound macrophages can break this cycle. In one approach, researchers coated isolated mitochondria with a polysaccharide that directed them to macrophages. In a diabetic mouse wound model, local delivery of these engineered mitochondria promoted wound repair, improved tissue structure, reduced oxidative damage, enhanced blood vessel formation, and shifted macrophages toward a healing-promoting state.19PubMed Central. Polysaccharide-engineered mitochondria reprogram macrophages to resolve diabetic wound inflammation and promote repair
A parallel study used extracellular vesicles from fat-derived stem cells as the delivery vehicle. These vesicles carried functional mitochondria into wound macrophages, restoring their central metabolic cycle and flipping them from an inflammatory to a reparative state. A single course of treatment in diabetic mice accelerated wound closure, improved new tissue formation, and reduced local inflammation. When the researchers depleted the mitochondria from the vesicles before treatment, the healing benefits largely disappeared, confirming that the mitochondrial cargo was doing the heavy lifting.20PubMed Central. Mitochondrial transfer via ADSC-EVs reprograms glucose/glutamine metabolism to restore TCA cycle-driven M2 polarization in diabetic wounds For the millions of people living with diabetic foot ulcers and other chronic wounds, this line of research represents a genuinely new therapeutic angle.
Early Human Trials
Animal data are encouraging, but therapies live or die on whether they work and are safe in people. The clinical picture is still very early, and results so far are mixed.
A phase 1 trial tested autologous mitochondrial transplantation, meaning the patient’s own mitochondria were harvested and reinjected, during reperfusion therapy for acute stroke. The approach proved safe: no significant adverse events were observed, and safety outcomes were comparable to matched controls who did not receive the transplant.21PubMed Central. Autologous mitochondrial transplant for acute cerebral ischemia: Phase 1 trial results and review Safety was the primary aim, not efficacy, so the trial was not designed to show whether the treatment improved recovery.
In cardiac medicine, a small randomized trial enrolled 30 patients with acute heart attacks. Half received standard care, and half received autologous mitochondria derived from their own platelets, delivered via injection into the coronary artery. The mitochondria group showed a slightly greater improvement in heart pumping function and a significant improvement in exercise capacity over 40 days. There was no meaningful difference between the groups in major cardiac events, abnormal heart rhythms, or hospital stay length, suggesting the procedure was safe.22PubMed. Safety and efficacy of platelet-derived mitochondrial transplantation in ischaemic heart disease The researchers themselves stressed that larger trials with longer follow-up are needed before drawing conclusions about real clinical benefit. Other reviews of the field have echoed this caution, noting that clinical trials using mitochondrial transplantation have shown mixed results overall.23PubMed Central. Mitochondrial transplantation: an overview of a promising therapeutic approach
Nanomaterials That Amplify Natural Transfer
Rather than harvesting and transplanting isolated mitochondria, some researchers are trying to crank up a cell’s own production of them, making more mitochondria available for natural intercellular sharing. One group used molybdenum disulfide nanostructures to stimulate mitochondrial biogenesis inside donor cells, achieving roughly a twofold increase in mitochondrial mass. This increase translated into several-fold higher efficiency of mitochondrial transfer to recipient cells, which showed improved respiratory capacity and energy production. In cellular models of mitochondrial damage, the enhanced transfer substantially restored cell function.24PubMed Central. Nanomaterial-induced mitochondrial biogenesis enhances intercellular mitochondrial transfer efficiency The approach is interesting because it sidesteps the whole problem of isolating, storing, and transporting fragile mitochondria. Instead, you boost the body’s own transfer machinery.
Another team engineered “super” extracellular vesicles that were enriched with mitochondria, with particles ranging from 350 to 950 nanometers in size. Using nano-flow cytometry and electron microscopy, they found that roughly six out of every ten released mitochondria ended up encapsulated inside vesicles, while the rest floated free.25Nature Communications. Super mitochondria-enriched extracellular vesicles enable enhanced mitochondria transfer Packaging mitochondria inside vesicles protects them from the harsh extracellular environment and may improve uptake by target cells, so increasing the encapsulation rate could be a practical route to making vesicle-based therapies more effective.
Metabolic Disease and Liver Function
The therapeutic potential extends well beyond acute injuries. In metabolic syndrome, a cluster of conditions including insulin resistance, chronic inflammation, and fatty liver, mitochondrial dysfunction is both a cause and a consequence. In an animal model, transplanting healthy mitochondria reduced insulin resistance, lowered inflammatory markers, restored mitochondrial energy balance, and improved calcium handling and fatty acid breakdown in liver cells.26PubMed. Mitochondrial transfer restores impaired liver functions by AMPK/mTOR/PI3K-AKT pathways in metabolic syndrome The fact that transferring healthy mitochondria could reset multiple disrupted metabolic pathways at once hints at why this approach is getting attention from researchers in fields far removed from cardiology or neurology.
Fertility and Embryo Rescue
One of the more unexpected applications involves reproductive medicine. Egg cells from older females often have lower mitochondrial function, which can impair embryo development after fertilization. Researchers tested whether injecting mitochondria from induced pluripotent stem cells into fertilized oocytes from aging mice could improve outcomes. The results were striking: embryos that received the stem-cell mitochondria showed rescued developmental potential and better implantation rates after transfer. Mitochondria from ordinary skin fibroblasts did not produce the same benefit, suggesting the source of the mitochondria matters.27Biology of Reproduction. Mitochondrial transfer from induced pluripotent stem cells rescues developmental potential of in vitro fertilized embryos from aging females
The picture is not uniformly positive, however. A separate study found that injecting mitochondria from somatic cells into aged mouse oocytes did not rescue fertilization or embryo development rates, even though mitochondrial function in those oocytes was clearly impaired.28Human Reproduction. Poor embryo development in post-ovulatory in vivo-aged mouse oocytes is associated with mitochondrial dysfunction, but mitochondrial transfer from somatic cells is not sufficient for rejuvenation The discrepancy may come down to the type of donor cell: mitochondria from pluripotent stem cells, which resemble embryonic cells, may be better matched to the metabolic needs of an early embryo than mitochondria from skin cells. Reproductive mitochondrial transfer remains at an early experimental stage, but it hints at potential future applications for age-related infertility.
Unsolved Problems
For all the progress, several practical barriers stand between laboratory findings and routine clinical use. The most fundamental is shelf life. There is currently no reliable method for preserving isolated mitochondria, so every therapeutic dose must be prepared and used fresh.29PubMed Central. Challenges in Promoting Mitochondrial Transplantation Therapy That is a logistical nightmare for anything beyond small-scale trials. Calcium toxicity in the extracellular environment continues to damage mitochondria during the gap between isolation and delivery, and while hydrogels and vesicle encapsulation offer partial solutions, none yet work at industrial scale.
Sourcing raises its own questions. Autologous mitochondria, taken from the patient’s own tissue, avoid immune concerns but require a surgical biopsy, typically from muscle, at a time when the patient may already be in acute crisis. Allogeneic sources, from a donor, are more practical but less proven in humans. Ethical and regulatory frameworks for mitochondrial therapeutics are still being developed, and standards for quality control, dosing, and storage need to be established before broader clinical adoption is possible.30PubMed Central. Unlocking the potential of mitochondrial transplantation: overcoming challenges and paving the way for routine therapeutic application The field also lacks agreement on how to measure whether transplanted mitochondria are actually functioning inside recipient tissue in a living patient, rather than simply being present. Until that measurement gap closes, distinguishing a real therapeutic effect from a placebo response in human trials will remain difficult.